Levofloxacin (Leviflox) Pediatric Dosing
For pediatric patients, levofloxacin dosing is age-dependent: 16-20 mg/kg/day divided every 12 hours for children 6 months to 5 years old, and 8-10 mg/kg/day once daily for children 5 to 16 years old, with a maximum daily dose of 750 mg. 1
Age-Based Dosing Algorithm
Children 6 months to 5 years:
- Dose: 16-20 mg/kg/day
- Frequency: Divided every 12 hours
- Maximum: 750 mg/day total
Children 5 to 16 years:
- Dose: 8-10 mg/kg/day
- Frequency: Once daily
- Maximum: 750 mg/day
Adolescents with skeletal maturity:
- Dose: 500 mg once daily (for certain indications like atypical pneumonia) 1
FDA-Approved Indications in Pediatrics
The FDA has specifically approved levofloxacin for pediatric patients ≥6 months for:
- Inhalational anthrax (post-exposure)
- Plague (treatment and prophylaxis)
For these indications, 8 mg/kg every 12 hours (not to exceed 250 mg per dose) achieves comparable steady-state exposures to adults receiving 500 mg once daily 2.
Important Formulation Considerations
Tablet limitations: Levofloxacin tablets can only be administered to pediatric patients weighing ≥30 kg due to available tablet strengths. For children <30 kg, alternative formulations (oral solution or dispersible tablets) should be considered 2.
Dispersible vs. non-dispersible formulations: Recent pharmacokinetic data shows dispersible tablets have approximately 29% higher bioavailability compared to crushed non-dispersible tablets 3, 4. This means:
- Dispersible tablets: 16-30 mg/kg may be required
- Crushed non-dispersible tablets: 20-38 mg/kg may be required to achieve equivalent exposures 4
Clinical Context from Guidelines
The 2011 PIDS/IDSA guidelines list levofloxacin as an alternative agent (not first-line) for pediatric community-acquired pneumonia, specifically for:
- Resistant Streptococcus pneumoniae (MIC ≥4.0 μg/mL)
- Haemophilus influenzae infections
- Atypical pathogens (Mycoplasma pneumoniae, Chlamydophila pneumoniae)
Critical Safety Warnings
Musculoskeletal risks: Pediatric patients treated with levofloxacin had significantly higher incidence of musculoskeletal disorders (2.1% at 60 days, 3.4% at 1 year) compared to non-fluoroquinolone-treated children (0.9% and 1.8%, respectively; p<0.05). Most disorders were mild-to-moderate arthralgia involving weight-bearing joints, with median resolution time of 7 days 2.
Pediatric clearance: Children clear levofloxacin faster than adults, resulting in lower plasma exposures for equivalent mg/kg doses. Clearance reaches 50% maturation at birth and 90% maturation at 8 months of age 2, 3.
Common Pitfalls to Avoid
- Don't use adult weight-based dosing: The per-kg dose in children is substantially higher than adults due to faster clearance
- Don't forget the maximum daily dose: Always cap at 750 mg/day regardless of calculated dose
- Don't use for routine infections: Reserve for resistant organisms or when β-lactams are contraindicated, given arthropathy concerns
- Don't assume all formulations are equivalent: Dispersible tablets provide higher bioavailability than crushed tablets